Phase IIa trial begins in alcohol use disorder patients
Clearmind Medicine launched a Phase IIa stage in its Phase I/IIa trial of CMND-100 for alcohol use disorder.
Results have not been presented; the update covers trial initiation and early enrollment rather than clinical outcomes.
Six patients have enrolled so far, starting the first multiple-dose treatment phase in participants with moderate-to-severe alcohol use disorder.
Study aims to assess safety, tolerability, and early signs of benefit, supporting a potential scalable, non-hallucinogenic psychedelic-derived treatment approach.
A prior independent safety review supported progression from the initial healthy-volunteer safety phase into later dosing stages.
CMND•
